The group's principal activities are research, development and commercialization of therapeutic platform technology, designed to treat diseases by harnessing the power of the human immune systems. The group had clinical progress in five disease indications: atherosclerosis, congestive heart failure, ischemia/reperfusion injury, autoimmune disease and graft-versus-host disease. The group's lead clinical program, now in late-stage development, is focused on the treatment of peripheral arterial disease.
